Dr. Zongjin Li is a Professor at the Department of Pathophysiology and a Director of the Laboratory of Molecular Imaging and Stem Cell Therapy at Nankai University School of Medicine, Tianjin, China. He received his PhD degree from Peking Union Medical College and completed his postdoctoral training in the Molecular Imaging Program (MIPS) at Stanford University, USA. He has published more than 120 peer-reviewed papers on molecular imaging and stem cell therapy.
Dr. Ramapuram Jayachandra Babu is currently a Professor and Graduate Program Officer at the Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University. He received his Bachelor’s degree in Pharmacy from the University of Madras and Masters and PhD degrees in Pharmaceutics from Indian Institute of Technology, Varanasi, India. His research interests include formulation development of nanoparticle based formulations for topical and oral delivery, solubility improvement of insoluble drugs, percutaneous penetration enhancement techniques, and transdermal drug delivery systems. He has authored and co-authored over 90 peer reviewed papers and 100 conference abstracts in several national and international conferences. He has served as a chair and co-chair of scientific sessions at the Annual National Meetings of American Association of Pharmaceutical Scientists and Society of Toxicology. He serves as an editorial board member for five journals and as a peer reviewer for more than forty journals. His field of expertise are Transdermal Drug Delivery; Nanoparticles, Solubility improvement; Ocular Drug Delivery.
Prof. Alexander Seifalian, worked at the Royal Free Hospital and University College London for over 26 years. During this time he spent a year at Harvard Medical School looking at the causes of cardiovascular disease and a year at Johns Hopkins Medical School looking at the treatment of liver cancer. He published more than 687 peer-reviewed research papers and registered 14 UK and International patents. He is the Editorial Board Member of 41 journals. He is currently a director of the Centre for Commercialization of Nanomaterials for Drug Delivery, Regenerative Medicine, and Medical Devices.
Maria J. Blanco‐Prieto received her degree of Pharmacy Degree from the University of Santiago de Compostela (Spain), followed by a PhD in Pharmaceutical Sciences from the University of Paris‐Sud (France). She completed post‐doctoral training at the Swiss Federal Institute of Technology (ETH), Zürich, (Switzerland) and then joined the University of Navarra where presently she is a Full Professor of Pharmacy and Pharmaceutical Technology. Her research interest is in the field of biomaterials and advanced drug carrier systems including the design and the development of polymer and lipid based micro‐ and nanoscale carriers, their biological evaluation in in vitro cell cultures and also their pharmacokinetic and dynamic impact in vivo (using relevant animal models of the diseases).
Dr. Darryl T. Martin is a Research Scientist at the Yale School of Medicine. He obtained his PhD from the Division of Biomedical Sciences, the Memorial University of Newfoundland in 2010. His research interests include drug delivery systems that target prostate and bladder cancers using nanoparticle-based platforms for diagnostic and therapeutic purposes.
Dr. Yu Nie obtained PhD in Pharmaceutical Sciences from West China School of Pharmacy, Sichuan University, China. She is presently serving as a Professor at NERCB, Sichuan University, China and before that she was an Assistant Professor at the same institution. She also has an experience as a postdoc fellow at Ludwig-Maximilian-University of Munich, Germany. Her research interests include Regenerated bio-materials, medicinal excipients in ophthalmology and Orthopedics. She has contributed more than 50 publications, having citations around 1050.
Dr. Dorkoosh received his PhD in pharmaceutics and biopharmaceutics from Leiden University, the Netherlands in 2002. He followed an international training on intellectual property and management of innovation at World Intellectual Property Organization (WIPO) in Geneva, Switzerland in 2005. He got his Diploma in management from Chartered Management Institute of London, UK in 2009. He is currently an associate professor at Tehran University of Medical Sciences. He is also the head of Patent office of Tehran University of Medical Sciences. Dr. Dorkoosh has published more than 80 research articles and held 10 patents and patent applications.
Dr. Murugan Ramalingam is a Professor at the Centre for Stem Cell Research (India). Concurrently, he is an Adjunct Professor at the Tohoku University (Japan). He worked as Associate Professor at the Université de Strasbourg (France) and Assistant Professor at the WPI-Advanced Institute for Materials Research (Japan). He has also worked at the U.S. National Institute of Standards and Technology (NIST) and the National Institutes of Health (NIH). He received his Ph.D. in Biomaterials from the University of Madras. He is the author of over 260 scientific publications.
Dr. Clare Hoskins obtained PhD in Pharmaceutics from Robert Gordon University, Aberdeen. She is presently serving as a Senior Lecturer in Pharmaceutics at Keele University. She is a member of different professional bodies such as Royal Society of Chemistry, Controlled Released Society, British Nano-medicine Society and Higher Education Academy. She has contributed numerous publications in different national and international journals. She also possesses different editorial responsibilities in different journals as a guest editor and editorial board member.
Dr. Kwon is the Jens T. Carstensen Distinguished Chair Professor in the School of Pharmacy at University of Wisconsin. He received the Jorge Heller Journal of Controlled Release/Controlled Release Society (CRS) Outstanding Paper Award (1994) and CRS Young Investigator Research Achievement Award (2003). He is a Fellow of the American Association of Pharmaceutical Scientists (2012) and a highly-cited researcher by Thomson Reuters in the category of Pharmacology & Toxicology (2014). He is co-founder of Co-D Therapeutics Inc., a start-up company dedicated to multi-drug anticancer nanotherapeutics.
Prof. Arote Rohidas is an Associate Professor and the director of Nanomedicine Laboratory in the Dept. of Molecular Genetics, School of Dentistry, Seoul National University. His research includes nanotechnology, drug delivery, molecular targeting, nucleic acid delivery, bioimaging and modulation of cell death mechanism has been published in over 50 international journals and also produced various patents.
Miguel Ferreira has a degree in Chemistry and a Masters in Medicinal Chemistry from the University of Minho, Portugal. He obtained his Ph.D. in Chemistry from the University of Minho in 2014. Since 2015, he has been a PostDoc at the Italian Institute of Technology, where he developed and translated The biomaterials based systems for applications in nanotheranostics and targeted drug delivery. He is in charge of producing the new prodrugs for their encapsulation into the nanoconstructs, and for the modification of the polymers to enhance their stability and to optimize their release rates.
Dr. Bhupendra Prajapati is a Professor in the Department of Pharmaceutics, Shree S.K. Patel College of Pharmaceutical Education and Research, Ganpat University, Gujarat, India. He has more than 20 years of academic and research experience and has published more than 100 research and review papers in international and national journals. Under his editorial ship, three books are under process and he has authored 20 book chapters in the field of novel drug delivery. He has published two Indian patents and three applications under are evaluation. He is a reviewer in three high impact journals and is on the editorial board of several scientific journals.
Dr. Hua Ai, PhD, is a Professor of Biomaterials, National Engineering Research Center for Biomaterials, Sichuan University; Adjunct Professor of Radiology, West China Hospital, Sichuan University. Dr. Hua is a Fellow of Biomaterials Science and Engineering (FBSE), and also a Fellow of American Institute for Medical and Biological Engineering (AIMBE). Dr. Hua is active in promoting international biomaterials academic exchanges through meetings, symposia and workshops. Dr. Hua focuses on the design and application of magnetic nanobiomaterials for molecular imaging and drug delivery. Dr. Hua has developed sensitive magnetic resonance imaging probes based on superparamagnetic iron oxide nanoparticles and paramagnetic molecules. One of Dr. Hua's probes is archived in Molecular Imaging and Contrast Agent Database (NIH's National Library of Medicine). Dr. Hua's most of the work has been carried out under clinical magnetic resonance imaging scanners.
Alaa A. Aljabali completed MRes in cancer biomarkers from Essex University and a Ph.D. in Bionanotechnology from John Innes Centre (UK). He worked as a postdoctoral research fellow at the University of Oxford on the development of nanoparticles as clinical imaging agents. Recently, he completed Fellowship in Responsible Conduct of Research at the University of California San Diego. His research interest are Biomaterials, Drug delivery and targeting, Material science, and Nanomedicine.
Giulio Caracciolo is Professor at the Molecular Medicine Department of the Sapienza University of Rome. He is mainly interested in understanding the bio–nano interactions between nanodelivery systems and physiological environments. The relationships between synthetic identity, biological identity and physiological response of drug delivery systems will enable researchers to predict their outcome after administration in vivo. This would represent a truly new paradigm in the field of pharmaceutics and nanomedicine.
Dr. Bin Chen is now a Full Professor and Vice Director at the State Key Laboratory of Multiphase Flow in Power Engineering, Xi’an Jiaotong University. He received his Ph.D in 2002 from Xi’an Jiaotong University, China. Afterwards, he worked as Postdoctoral Research Fellow of Japan Society for the Promotion of Science from 2002 to 2004. For more than a decade, Dr. Chen has devoted his efforts to the research on laser dermatology, in particular with the laser treatment of Port Wine Stain. He is currently working on photothermal-activatable liposomal drug delivery, blood absorption enhancement by nano-particle, as well as animal experiment on thermal damage of blood capillary by 595nm and 1064nm laser. He has published over 50 peer-reviewed journal papers and was invited for more than 20 keynote speeches.
Pieter R. Cullis, Ph.D. FRSC is the Director of Life Sciences Institute at the University of British Columbia (UBC) He is a Professor in the Department of Biochemistry and Molecular Biology and Director of the, NanoMedicines Research Group, UBC. Dr. Cullis and co-workers made fundamental advances in the generation, loading and targeting of lipid nanoparticle (LNP) systems for intravenous delivery of small molecule drugs and macromolecular drugs such as small interfering RNA (siRNA). This work has contributed to three drugs that have been approved by regulatory agencies in the U.S. and Europe for the treatment of cancer and its complications. Dr. Cullis has co-founded ten biotechnology companies, has published over 300 scientific articles and is an inventor of over 60 patents. He also co-founded the BC Personalized Medicine Initiative in 2012. Dr. Cullis received many awards and was elected as the Fellow of the Royal Society of Canada in 2004 and was awarded the Prix Galien, Canada’s premier prize for achievements in pharmaceutical R&D, in 2011.
Dr. Sudip Das is a professor of pharmaceutical sciences at Butler University, College of Pharmacy & Health Sciences. He is also an Adjunct Professor in the School of Medicine, Indiana University. He was the chair of the department of pharmaceutical sciences and the director of the graduate program in pharmaceutical sciences at Butler University. Dr. Das has over thirty years of teaching and research experience in the professional pharmacy and graduate programs in the USA and Canada. His current research involves targeted delivery of siRNA and anticancer drugs for the treatment of breast cancer and glioblastoma. Dr. Das has over 150 research publications, review articles, patents, proceedings, conference presentations, and book chapters, is a recipient of multiple awards/honors, and has secured extramural research funding from NIH, PDA, and several pharmaceutical industries.
Nunzio Denora received the degree in Chemistry and Pharmaceutical Technology from the University of Bari in 2001 and obtained his Ph.D. in Pharmaceutical Technology from the University of Palermo in 2004. After a postdoctoral position in the Department of Pharmaceutical Chemistry at Kansas University (2005-2006), he was appointed as assistant professor and research scientist of Pharmaceutical Technology in the Department of Pharmacy - Drug Sciences of the University of Bari. He has published more than 80 articles, is author of 3 book chapters, more than100 posters and several oral presentations and is inventor of 3 patents.
Dr. Martin J. D’Souza obtained his Ph.D. degree (1987) in Pharmaceutical Sciences from the University of Pittsburgh, Pittsburgh, PA, USA. Dr. D’Souza is currently performing numerous roles at Mercer University, Atlanta, GA, USA, i.e. Professor & Director of Graduate Programs in the College of Pharmacy. He is the Director of Mercer Clinical Laboratory, Co-Director of the Center for Drug Delivery Research, and Chair of the Pharmaceutics. He is the co-founder of Drug Delivery Therapeutics. His main fields of specialization include Vaccines, Pharmacokinetics, Bio-pharmaceutics, Bio-technology, etc.
Dr. Christine Dufès is a Senior Lecturer at the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), University of Strathclyde, Glasgow, United Kingdom. She obtained a Doctorate in Pharmacy and a PhD from the University of Poitiers (France). Her research interests include the targeted delivery of drugs and therapeutic genes to tumours and cerebral diseases. She has been awarded the Biochemical Journal Young Investigator Award (2009) and the Tom Gibson Memorial Award (2012) for her research, in addition to the Best Overall Strathclyde Teaching Excellence Award 2013 for her teaching. She sits on the editorial boards for 17 journals.
Fabio Rocha Formiga obtained a PhD in pharmaceutical technology from the University of Navarra (Spain) in 2011. He is the co-founder and vice-president of the Brazilian Chapter of Controlled Release Society since 2019. He is a member of the Brazilian Association of Pharmaceutical Sciences (ABCF) and the European Foundation for Clinical Nanomedicine (CLINAM). Currently, Dr. Formiga is a scientist at Oswaldo Cruz Foundation and a tenured adjunct professor at the University of Pernambuco in Brazil. He has been acknowledged with the Research Award from Spanish Society of Pharmaceutics and Pharmaceutical Technology (SEFIG) in 2013. His research is focused on pharmaceutical nanotechnology and drug delivery.
Dr. Biana Godin earned Ph.D. in Pharmaceutical Sciences from the School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel. During Ph.D. studies, Dr. Godin focused on designing a non-invasive treatment for the hard-to-treat deep skin infections and on nasal delivery of proteins. Dr. Godin completed a postdoctoral fellowship in Cancer Nanotechnology from the Institute of Molecular Medicine, University of Texas Health Sciences Center in Houston. Dr. Godin's postdoctoral research focused on design and evaluation of injectable nanotherapies for cancer treatment and imaging. Dr. Godin is a Scientist and Associate Professor in the Department of Nanomedicine at Houston Methodist Research Institute. Dr. Godin's lab focuses on developing physiologically relevant in vitro and in vivo disease models and exploiting physical and biological mechanisms to improve the currently available therapeutic options in oncology, infectious diseases and obstetrics. Dr. Godin is a translational scientist on the interception of biological and physical sciences, with the ultimate goal of bringing advanced and safe therapies and therapy personalization methods into the clinic to benefit patients. Dr. Godin has a number of scientific publications, and has received multiple federal and foundation-based grants, and participated in national and international grant review panels. Dr. Godin holds academic positions at the Department of Nanomedicine and Department of Obstetrics and Gynecology, Institute of Academic Medicine, Houston Methodist Research Institute, Cancer Center Houston Methodist Hospital; Adjunct Faculty at the Department of Obstetrics, Gynecology and Reproductive Sciences, University of Texas Health Science Center School of Medicine; and at the Department of Biomedical Engineering, Texas A&M University.
Khaled Greish is Associate Professor of Molecular Medicine, and head of the Nano-research unit, at Princes Al-Jawhara Centre, Arabian Gulf University, Kingdom of Bahrain, and Adjunct Associate Professor of Pharmaceutical Chemistry at University of Utah, USA. He Published > 70 peer reviewed papers, and 10 book chapters in the field of targeted anticancer drug delivery. Controlled Release Society (CRS) awarded him the CRS Postdoctoral Achievement award in 2008 and in 2010; he was elected as the member of the CRC College of Fellows in 2014 at the University of Otago.
Professor Zhongwei Gu graduated from Peking University in 1981 and served as a senior visiting scholar in the Research Triangle Institute, RTP and the University of Utah, USA, respectively from 1984 to 1986 and 1991 to 1993. He was appointed as a Professor in 1994, and has thrice been the Chief Scientist of the National Basic Research Program of China (the 973 program) since 1999. He is a Fellow of International Union of Societies for Biomaterials Science and Engineering (FBSE). His current research activities focus on the biomedical polymers, nano-biomaterials and drug delivery systems and tissue engineering.
Dr. Jianfeng Guo, Ph.D., is a Professor of Nanomedicine at School of Pharmaceutical Sciences, Jilin University, China. He received his PhD in 2011 from University College Cork (UCC), Ireland. He was a Research Fellow at University of Michigan, Ann Arbor, followed by industrial working experience at the Viva Biotech Ltd., Shanghai, as a Project Manager. He then spent three years at UCC as a Senior Research Fellow, prior to joining in Jilin University in 2016. He was awarded the Embark Initiative Postgraduate Scholarship, Chinese Government Award for Outstanding Self-financed Students Abroad. Dr. Jianfeng Guo has published 24 peer-reviewed scientific articles.
Dr. Umesh Gupta, currently working as Assistant Professor in the Department of Pharmacy, Central University of Rajasthan, India. He did Ph.D. in Pharmaceutical Sciences from Dr. H. S. Gour University, Sagar, India under the mentorship of Prof. NK Jain. He has recently been awarded “DAAD Research Stays for Academics and Scientists” at Leibniz-institut fur Polymerforschung Dresden, Germany. He has the past experience of working as Research Scientist at Ranbaxy Research Laboratories, India and Post-Doctoral Research Associate at South Dakota State University, USA. He joined the Central University of Rajasthan in the year 2013.
Ulrich Lächelt studied pharmaceutics at the University of Heidelberg and received a doctoral degree in Pharmaceutical Biology at the LMU Munich in 2014. He worked on multifunctional sequence-defined nucleic acid carriers together with Prof. Ernst Wagner. Since 2017 he continues the research on drug delivery and nanomedicine as junior research group leader and candidate for habilitation. He is an extraordinary member of the Center for NanoScience (CeNS) at the LMU. His research focuses on the intracellular delivery of biomacromolecules, such as nucleic acids, peptides and proteins, the development of drug conjugates and inorganic-organic hybrid nanopharmaceuticals.
Dr. Xinn- Guii Lii obtained PhD in Polymer Materials from China Textile University, Shanghai. He is presently serving as Professor of Polymer Materials and Director of Inst. of Mater Chem at Tongji University, Shanghai, China. He has been recognized with many awards and honors such as ACS Membership Award in 2015, Natural Science Prize in 2015 and many other awards. He is also a member of different organizations such as ACS, National Engineering Research Center of Electronic Circuits Base Materials of China, Key Laboratory of Advanced Polymer Materials, Shanghai, China, Educational Ministry of China, and Shanghai Key Laboratory for Advanced Polymer Materials.
Dr. Madhankumar, Achuthamangalam B. is an Assistant Professor from 2008 in the Department of Neurosurgery, Pennsylvania State University College of Medicine, Hershey, PA. from 2004 – 2008, he has been the Instructor in the Department of Neurosurgery, Pennsylvania State University College of Medicine, Hershey, PA. He completed his Ph.D from University of Madras, India in 1999 in Chemistry-Drug Delivery System. He did Post Doc from Penn State University College of Medicine, Hershey, PA in Molecular Targeting-Cancer Therapy in 2004. He has membership in different associations, such as Member in American Association for Advancement in Science (AAAS), Member in the American Association for Cancer Research (AACR), Member in the Society for Neuro-oncology (SNO), etc. He has published in a number of peer-reviewed journals. He has been involved in the research support of a number of project, such as 5R01CA169117 (Role: Co-Investigator) NIH/NCI (subaward from Cleveland Clinic Foundation) Targeting Ferritin in Glioblastoma, Grant 153578 (Role: Co-investigator) Woodward Endowment-Targeted Delivery of a Potent Anti-proliferative Metal Chelator to Brain Tumors.
Tamara Minko, Ph.D., is a Distinguished Professor and Chair of the Department of Pharmaceutics at Rutgers University. Her current research interests include nanotechnology; drug delivery; personalized nanomedicine; molecular targeting; nucleic acids delivery; mechanisms of multidrug resistance; bioimaging; preclinical evaluation of new therapeutics; and modulation of cell death mechanisms during hypoxia. Professor Minko is author and coauthor of more than 400 publications. Dr. Minko is an elected Fellow of CRS, AAPS, and AIMBE; recipient of numerous awards. She also is an Executive Editor of Advanced Drug Delivery Reviews, Editor of Pharmaceutical Research, President-Elect of the Controlled Release Society.
Teresa Musumeci is an assistant professor and research scientist in the Department of Drug Sciences at the University of Catania, since 2008. Teresa Musumeci received her Pharmacy degree from the University of Catania (Italy) in 2001. She received her PhD in Pharmaceutical Technology from the University of Palermo (Italy) in 2007. She is the author of 30 per-reviewed papers and 2 book chapters. Her scientific activity is focused on design and characterization of nanocarriers for delivery of drugs.
Dr. Qiang Peng obtained his B.S. degree (2006), M.A. degree (2009), and Ph.D in pharmaceutics (2012) from Sichuan University, China. He joined West China Hospital of Stomatology, Sichuan University as a lecturer in 2012 and promoted as an associate professor in 2014. Dr. Peng once worked in Keele University from 2010 to 2011 and in University of Copenhagen during 2015.
His research focuses on nanomaterials‐based advanced drug delivery. As a young scientist, he has published more than 20 publications. He won the Sichuan Provincial Award of Outstanding PhD Dissertation in 2014 and the First Prize of Chinese Outstanding Young Investigator Award, IADR‐China Division in 2014.
Dr. Santos obtained a doctorate (D.Sc.) in Chemical Engineering from the Helsinki University of Technology, Helsinki, Finland. Currently Dr. Santos is an Adjunct Professor in Pharmaceutical Nanotechnology at the University of Helsinki, Finland. He has published more than 150 scientific publications. Dr. Santos serves as Editor and is in the Editorial Board of several international journals.
Sevda Şenel is Professor at the School of Pharmacy at Hacettepe University, Ankara Turkey. Numerous international (NATO‐CRG, NATO‐CLG, British Council, EU‐7‐SME) and national (TUBITAK, SAN‐TEZ) projects led her group to the development of non‐invasive systems for drugs and vaccines via various mucosae (buccal, sublingual and nasal) in human and veterinary field. Dr. Şenel and her research group has been awarded a number of prestigious honors including AAPS‐PharmSciTech Best Poster Award (2015), Hacettepe University Science Award (2011), The Distinguished Scientist Award ‐ by the Academy of Science of the Turkish Pharmacists Association (2010), CRSIntervet Best Veterinary Paper Award (2005) and the Novartis Pharmaceutical Technology Research Award (2004). Dr. Şenel is the author of more than 150 research publications, which includes original research and book chapters.
Amanda K. A. Silva obtained a degree in Pharmacy in 2005 at UFRN, Brazil, and a PhD in Pharmaceutical Technology in 2008 in the domain of gastro-resistant magnetic microcapsules. She obtained a second PhD in Cellular and Molecular Biology in 2010 from the Université d’Evry, France concerning polysaccharides for thermo-controlled cell culture in 3D. In 2013, Amanda obtained a tenured CNRS researcher position at Matter and Complex Systems lab in Paris. She works in physical approaches for regenerative medicine, extracellular vesicle engineering, theranosis and photo-activated therapies. Amanda has published 37 papers and is an inventor in 4 patents.
Vladimir P. Torchilin, Ph.D., D.Sc. is a University Distinguished Professor of Pharmaceutical Sciences and Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston. His interests include drug delivery and targeting, nanomedicine, multifunctional and stimuli-sensitive pharmaceutical nanocarriers, biomedical polymers, experimental cancer therapy. He has published more than 400 original papers, more than 150 reviews and book chapters, wrote and edited 12 books, and holds more than 40 patents. Google Scholar has shown more than 44,000 citations of his papers with an H-index of 96. He is Editor-in-Chief of Current Drug Discovery Technologies, Drug Delivery, and OpenNano, Co-Editor of Current Pharmaceutical Biotechnology and on the Editorial Boards of many other journals. He received more than $30 M from the governmental and industrial sources in research funding. He has multiple honors and awards and in 2011, Times Higher Education ranked him number 2 among the top world scientists in pharmacology for the period of 2000-2010.
Dr. Wagner is Professor of Pharmaceutical Biotechnology at Ludwig-Maximilians-Universität Munich and a member of the Munich Center for Nanoscience. He coordinates ‘Biomedical Nanotechnologies’ of the Excellence Cluster ‘Nanosystems Initiative Munich’. After a Ph.D. in Chemistry from the Technical University of Vienna and a postdoctoral stay at the ETH Zurich, he was the group leader at the IMP Vienna and Director for Cancer Vaccines at Boehringer Ingelheim Austria. Dr. Wagner has authored more than 390 publications with an h-index 70. He has been a board member of the German Society for Gene Therapy, Committee member of ASGCT, and BSA member of the CRS.
Professor Walker completed his Ph.D. degree in Biopharmaceutics and Pharmacokinetics at Rhodes University in Grahamstown, South Africa. He is the former Dean and Head of the Faculty of Pharmacy at Rhodes and is currently the Professor of Pharmaceutics and is the current chair of the Academy of Pharmaceutical Sciences in South Africa. Professor Walker has published and presented over 200 scientific outputs and serves on the editorial boards of a number of journals. Professor Walker undertakes research studies in all aspects of drug delivery and product development.
Zimei Wu is an Associate Professor at the School of Pharmacy, University of Auckland, New Zealand (NZ). She holds a PhD from University of Otago (NZ) and a Masters from China Pharmaceutical University. Her ‘liposomes’ research has attracted wide collaborations. She received an NZ-China Scientist Exchange Award from the Royal Society of NZ. She also researches transdermal delivery with successful stories featured on NZ TV3. Zimei also serves on editorial boards of Journal of Liposome Research, and Pharmaceutical Development and Technology and a referee for >20 journals. Zimei was the past President of NZ Local Chapter of Controlled Release Society.
Prof. Zhao is a Full Professor of Pharmaceutics in the School of Pharmaceutical Science and Technology, Health Science Platform, Tianjin University. He obtained the Bachelor (Polymer), Master (Engineering), and PhD (Pharmacy) degree from Dalian University of Technology, Dalian Institute of Chemical Physics (CAS), and King’s College London, respectively. His research interests focus on pharmaceutical micelles, stimuli-responsive drug delivery, and ferroptosis antitumor nanomedicine.
Dr. Goutam Mondal is an emerging pharmaceutics and drug delivery scientist. He is an expert in the design and synthesis of receptor targeted lipids and polymeric systems, the techniques of animal tissue culture, tumor growth inhibition studies, and pharmacokinetics studies of small molecules. Presently, he is associated with Dr. Ikhlas A Khan’s research group under supervision of Dr. Ryan Yates at the National Center for Natural Products Research, University of Mississippi, USA where he is actively involved in pre-clinical and clinical pharmacokinetics and pharmacodynamics of natural products. He has published 21 research articles in high impact peer-reviewed journals.
Dr. Mariane Lira Nogueira is a Pharmacist. She obtained Master's degree in Pharmaceutical Sciences, and Ph.D. in Biological Sciences with an emphasis on Biotechnology. She completed an interuniversity exchange doctorate in Pharmacotechnics (2007-2008) at the Faculté de Pharmacie - Université Paris Sud 11 and an internship at the Universidad de Navarra (2008). She did Post-doc from the Université Paris Saclay (2014-2015). She is currently an Associate Professor at the Federal University of Pernambuco, Brazil, a researcher at the Keizo-Asami Immunopathology Laboratory, and leader of Nanotechnology, Biotechnology, and Cell Culture Research Group. Her research fields are mainly focused on the development and characterization of surface-modified nanocarriers for biomedical applications.
Dr. Meisam Omidi is an Assistant Professor of Protein Research Center, Shahid Beheshti University. Dr. Omari’s research is focused on application of nanobiomaterials in soft, hard, and interfacial tissue engineering. He is particularly interested to design and fabricate smart nano drug delivery systems for regenerative medicine application. He has (co)authored over 80 research papers in the field of nanoscience and nanotechnology.
Dr. Aniruddha Roy is currently working as an Assistant Professor in the Department of Pharmacy at Birla Institute of Technology and Science (BITS) - Pilani, India. He is a Pharmaceutical Technologist by training. He completed PhD in Immunology from National Institute of Immunology (NII), New Delhi, India. His main area of PhD thesis work was immunotherapy of cancer. After PhD, he worked at the Indian Institute of Technology, New Delhi, Ontario Institute for Cancer Research at the University of Toronto, Canada, and University of British Columbia, Canada in various capacities. He has more than ten years of research experience. His research is primarily focused on nanomedicine and targeted drug delivery in different diseases.
Dr. Purnendu Kumar Sharma is a Scientist with over 9 years of R&D experience in discovery and early-stage development of pharmaceutical and biopharmaceuticals. He has earned his Ph.D. in Pharmaceutical Sciences from the University of Mississippi, where he made major contributions in the fields of drug product development, characterization and technology development. He has expertise in formulation development, in-vitro, ex-vivo and in-vivo evaluations of sterile drug products, cell therapy drug product, biologics, topical and transdermal drug delivery platforms for various indications. He authored more than 19 research publications in various peer reviewed journals and 1 book chapter. Currently, he is working in Takeda Pharmaceuticals, where he is responsible for early-stage platform development and innovations in drug products.